---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-330804"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2026-08-03T21:06:22+00:00"
generated_at: "2026-08-03T21:08:11.642273+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics files prospectus supplement for up to $200M ATM offering

## Summary
- Filed prospectus supplement on Aug 3, 2026 to sell up to $200M of common stock.
- Shares offered under existing Controlled Equity Offering Sales Agreement with Cantor Fitzgerald.
- Prospectus supplement part of automatic shelf registration statement filed March 18, 2026.
- Legal opinion of Fenwick & West LLP filed as Exhibit 5.1.

## SEC filing metadata
- accession: 0001193125-26-330804
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2026-08-03T21:06:22+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/0001193125-26-330804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/d135735d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-330804
- JSON: https://secwatch.observer/filing/0001193125-26-330804.json
- Plain text: https://secwatch.observer/filing/0001193125-26-330804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.